Nuri Braintech

Company Overview

Snapshot

Founded in July 2024 by Dan Rappaport and Miri Polachek, Nuri Braintech operates with 1–10 employees. The company has secured funding across two rounds. In April 2025, embARC Ventures led a Pre-Seed funding round, highlighting early investor confidence in the company's innovative approach.

Business overview

Nuri Braintech is developing the first emotion brain-computer interface (eBCI) for psychiatry, aiming to transform care for individuals with severe, treatment-resistant psychiatric conditions. Its core technology involves an implantable platform that detects, decodes, and recalibrates trauma responses through real-time, closed-loop neuromodulation via Deep Brain Recoding (DBR). The company focuses on personalizing protocols to each patient's neural signature and retraining emotional patterns using native learning mechanisms and adaptive stimulation, initially targeting PTSD and planning to expand across other psychiatric indications. Nuri Braintech operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving the healthcare industry.

Company Intelligence Q&A

What is Nuri Braintech's core technology?

Nuri Braintech has developed the first emotion brain-computer interface (eBCI) for psychiatry. This implantable platform detects and decodes dysfunctional emotional circuits and delivers real-time, closed-loop neuromodulation through Deep Brain Recoding (DBR).

When was Nuri Braintech founded and by whom?

Nuri Braintech was founded in July 2024 by Dan Rappaport and Miri Polachek.

Which investor participated in Nuri Braintech's Pre-Seed funding round?

In April 2025, embARC Ventures participated in Nuri Braintech's Pre-Seed funding round.

What type of non-equity funding did Nuri Braintech receive?

In July 2025, Nuri Braintech secured a grant from the Israel Innovation Authority.

What specific psychiatric condition does Nuri Braintech initially target?

Nuri Braintech's technology initially targets severe, treatment-resistant forms of PTSD, with plans to expand across other psychiatric indications.